アドレナージック刺激がヒトのアクションポテンシャル持続時間回復に与える影響
Peter Taggart1, Peter Sutton, Zaid Chalabi
1The Hatter Institute, Department of Cardiology, University College London HospitalsLondon, WC1E 6DB. peter.taggart@uclh.org.
Circulation
|January 23, 2003
まとめ
イソプレナリンやアドレナリンなどのアドレナリン活性剤は,ヒトのアクションポテンシャル持続時間 (APD) の回復傾きを急激にします. この発見は,交感性の活動がどのように心房細動を促すかを説明するかもしれない.
科学分野:
- 心血管生理学 心血管の生理学
- 電気生理学 電気生理学
背景:
- 交感活動が心房不律に影響する.
- アクションポテンシャル持続時間 (APD) の回復は,心筋の電気的安定性の鍵です.
- より急なAPD還元斜面は,波折や心房細動を引き起こす可能性があります.
研究 の 目的:
- 人体におけるAPD回復に対するアドレネルジック刺激の効果を調査する.
- アドレナージックアゴニストがAPD回復の傾きを変更するかどうかを判断する.
主な方法:
- 18人の患者で右心室隔膜から記録された単相行動ポテンシャル.
- 600,500,および400msのサイクルの長さで構築されたAPD還元曲線.
- 測定中にイソプレナリンまたはアドレナリンの注入.
主要な成果:
- アドレナリンアゴニスト (イソプレナリン,アドレナリン) は,APD回復の最大傾斜の急さを大幅に増加させた.
- この効果は,より短い基本サイクルの長さでより顕著でした.
- 制御条件では,より長い基本サイクルの長さでより急な斜面を示した.
結論:
- イソプレナリンとアドレナリンは,ヒトのAPD回復斜面の急さを増強する.
- APDの回復に対するこのアドレナージック効果は,心房細動の促進に寄与する可能性があります.
関連する概念動画
Adrenergic Receptors (Adrenoceptors): Classification
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
Adrenergic Receptors: β Subtype
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Agonists: Direct-Acting Agents
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Adrenergic Agonists: Mixed-Action Agents
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...


